Intech Investment Management LLC Has $152,000 Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Intech Investment Management LLC lifted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 72.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 71,323 shares of the company’s stock after buying an additional 29,992 shares during the quarter. Intech Investment Management LLC’s holdings in Allogene Therapeutics were worth $152,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of ALLO. Zacks Investment Management bought a new position in Allogene Therapeutics during the third quarter worth $1,446,000. Geode Capital Management LLC boosted its position in shares of Allogene Therapeutics by 14.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after purchasing an additional 407,070 shares in the last quarter. abrdn plc bought a new position in shares of Allogene Therapeutics during the 4th quarter worth about $776,000. Vontobel Holding Ltd. grew its stake in shares of Allogene Therapeutics by 788.4% in the 4th quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock valued at $416,000 after buying an additional 173,457 shares during the period. Finally, Barclays PLC increased its position in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after buying an additional 172,745 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Price Performance

Shares of ALLO stock opened at $1.56 on Friday. Allogene Therapeutics, Inc. has a one year low of $1.32 and a one year high of $4.58. The firm has a 50-day moving average of $1.86 and a 200-day moving average of $2.26. The company has a market cap of $338.93 million, a P/E ratio of -1.00 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. As a group, research analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David D. Chang sold 46,668 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now directly owns 5,276,569 shares in the company, valued at $10,342,075.24. The trade was a 0.88 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,866 shares of company stock valued at $194,461. 24.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. HC Wainwright reduced their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.29.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).